Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | GPR183 | P32249 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22926630 | 0.90 | POLB (0.56) | SMN1; SMN2ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL13646643 | 0.89 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL12431599 | 0.89 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL13373550 | 0.87 | HPGD (0.58) | SMN1; SMN2ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL1063453 | 0.86 | L3MBTL1 (0.57) | SMN1; SMN2ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL1855882 | 0.86 | HPGD (0.61) | SMN1; SMN2ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL29565081 | 0.86 | HPGD (0.61) | SMN1; SMN2ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL1855879 | 0.86 | HPGD (0.61) | SMN1; SMN2ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL14559800 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL1063794 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1MAPTKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-1511742-B1 | KINASE INHIBITORS | CYTOPIA RES PTY LTD (AU) | 2010-02-03 | — | — | EP | disclosed |
| EP-1511742-B1 | KINASE INHIBITORS | CYTOPIA RES PTY LTD (AU) | 2010-02-03 | — | — | EP | disclosed |
| US-7598272-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| US-7598272-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| US-7598272-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| US-7511047-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2009-03-31 | — | — | US | disclosed |
| US-7511047-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2009-03-31 | — | — | US | disclosed |
| US-7259179-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-08-21 | — | — | US | disclosed |
| US-7259179-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-08-21 | — | — | US | disclosed |
| US-20070161635-A1 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-07-12 | — | — | US | disclosed |
| US-20070161635-A1 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-07-12 | — | — | US | disclosed |
| US-7189739-B2 | Compounds and methods to treat cardiac failure and other disorders | SCIOS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20060270687-A1 | Kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2006-11-30 | — | — | US | disclosed |
| US-20060241112-A1 | Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2006-10-26 | — | — | US | disclosed |
| EP-1511742-A1 | KINASE INHIBITORS | Cytopia PTY Ltd (AU) | 2005-03-09 | — | — | EP | disclosed |
| US-20050004140-A1 | Kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2005-01-06 | — | — | US | disclosed |
| WO-2003099811-A1 | KINASE INHIBITORS | CYTOPIA PTY LTD (AU) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270687-A1 | Kinase inhibitors | MAP3K20, MAP3K1, MAP3K19 | SMN1; SMN2 1468/4885ALDH1A1 3238/4885MAPT 597/4885 |
| US-20060241112-A1 | Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states | MAP4K2, MAP4K5, MAP4K4 | SMN1; SMN2 827/4885ALDH1A1 3757/4885MAPT 473/4885 |
| US-20050004140-A1 | Kinase inhibitors | MAP3K20, MAP3K1, MAP3K19 | SMN1; SMN2 1468/4885ALDH1A1 3238/4885MAPT 597/4885 |
| US-20070161635-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K10 | SMN1; SMN2 1668/4885ALDH1A1 3695/4885MAPT 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.